<DOC>
	<DOCNO>NCT01123499</DOCNO>
	<brief_summary>Background : - Many treatment immune system disorder involve use stem cell collect blood marrow . To obtain stem cell without surgery , individual receive granulocyte colony-stimulating factor ( G-CSF ) encourage production stem cell collect blood donation . However , patient normal donor respond G-CSF alone . - Plerixafor , recently approve Food Drug Administration , different G-CSF also allow stem cell collect donate blood . However , research need quality viability stem cell collect use G-CSF plerixafor . Objectives : - To collect study blood cell produce treatment G-CSF plerixafor healthy volunteer . Eligibility : - Healthy volunteer 18 65 year age eligible donate blood . Design : - Participants screen medical history , physical examination , initial blood test . - At start study cycle , participant receive daily morning injection G-CSF 5 day . These may give clinical center participant teaching , depend participant preference . - On morning Day 4 , participant visit clinical center provide blood sample injection . On even Day 4 , participant receive injection plerixafor . - Participants final injection G-CSF morning Day 5 , provide another blood sample . - On Day 5 , participant apheresis separate stem cell rest blood . The apheresis may take 5 hour complete . - The study end follow-up phone call 7 14 day apheresis procedure .</brief_summary>
	<brief_title>Collection Peripheral Blood Stem Cells Using G-CSF Plerixafor Normal Volunteers</brief_title>
	<detailed_description>Hematopoietic stem cell mobilize bone marrow peripheral circulation readily collect apheresis , may use several purpose . They use allogeneic autologous transplantation often manipulate various way depend goal transplant . Gene therapy immunodeficiency rely collection cell . Traditionally , mobilization do use granulocyte colony stimulate factor ( G-CSF ) . However patient normal donor respond GCSF alone . Plerixafor , recently Food Drug Administration ( FDA ) approve drug , unique mode action distinct GCSF , also result mobilization peripheral blood progenitor circulation , allow collection standard apheresis . The quality cell transduction use viral vector anticipation gene therapy use thoroughly assess , theoretical consideration vector use various envelope cell bind may affect use CXCR4 antagonist . In order able ass transduction engraftment cell murine model , perform collection mobilization 5 healthy volunteer NIH Clinical Center use FDA approve medication G-CSF plerixafor .</detailed_description>
	<mesh_term>JM 3100</mesh_term>
	<criteria>INCLUSION CRITERIA : To eligible participate study , subject must satisfy follow criterion : 1 . The subject must healthy adult age 1865 year , weigh least 50 kg . 2 , The subject must normal renal function ( creatinine &lt; 1.5 mg/dL ; &lt; 1 plus proteinuria ) ; normal hepatic function ( bilirubin &lt; 1.5 mg/dL ) ; normal hematologic function ( WBC great equal 2500/mm ( 3 ) ; granulocytes great equal 1200/mm ( 3 ) ; platelet great equal 120,000 ; hematocrit great equal 38 ) . 3 . A female childbearing potential may enter use 1 2 form effective contraception ( depend type contraception ) , negative serum pregnancy test within 1 week begin GCSF administration . 4 . The subject must willing allow blood cell sample store . EXCLUSION CRITERIA : A subject ineligible participate study follow criterion meet : 1 . The subject temperature &gt; 38 degree Celsius , WBC &gt; 9000/mm ( 3 ) . 2 . A female pregnant lactating determine history and/or pregnancy test . 3 . The subject history vasculitis , uncontrolled hypertension , symptomatic coronary artery disease , similar disorder . 4 . The subject positive test result follow : human immunodeficiency virus ( HIV ) I &amp; II antibody , hepatitis C virus ( HCV ) antibody , hepatitis B soluble antigen ( HBSAg ) , rapid plasma reagin ( RPR ) test syphilis . 5 . The subject lack peripheral venous access arm vein adequate apheresis . 6 . The subject currently participate research study . 7 . The subject may exclude discretion Principal Investigator ( PI ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 8, 2016</verification_date>
	<keyword>G-CSF</keyword>
	<keyword>Plerixafor</keyword>
	<keyword>Normal Volunteer</keyword>
	<keyword>Apheresis</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>HV</keyword>
</DOC>